News Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 16:05:00 23/06/2025 BST			5-day change	1st Jan Change
4.510 ^USD	0.00%		-1.31%	-5.64%

06-12	Vanda Pharmaceuticals Inc., Q1 2025 Earnings Call, May 07, 2025
06-10	Vanda Pharmaceuticals Inc. Announces First Patient Dosed in A Trial Evaluating VCA-894A in Charcot-Marie-Tooth Disease Type 2S	CI

Vanda Pharmaceuticals Inc., Q1 2025 Earnings Call, May 07, 2025	06-12
Vanda Pharmaceuticals Inc. Announces First Patient Dosed in A Trial Evaluating VCA-894A in Charcot-Marie-Tooth Disease Type 2S	06-10	CI
Vanda Pharmaceuticals Announces First Patient Dosed In A Trial Evaluating VCA-894A In Charcot-Marie-Tooth Disease Type 2S	06-10	RE
Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S	06-10	PR
Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025	05-16	PR
Vanda: Q1 Earnings Snapshot	05-07	AQ
Vanda Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	05-07	CI
Vanda Pharmaceuticals Inc. Reiterates Revenue Guidance for the Full Year 2025	05-07	CI
Vanda Pharmaceuticals Says FDA Accepts Bysanti Application for Bipolar I, Schizophrenia	05-05	MT
Drugmaker Vanda Announces Bysanti NDA Filing	05-05	RE
Vanda Pharmaceuticals Inc. Announces Bysanti NDA Filing	05-05	CI
Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025	05-02	PR
Vanda Pharmaceuticals Inc. v. FDA: Industry's Latest Attempt To Clarify Off-Label Promotion Rules	04-27	AQ
FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA	04-23	PR
Vanda Pharmaceuticals Seeks US FDA Approval for Bysanti to Treat Schizophrenia, Acute Bipolar I Disorder	03-31	MT
Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia	03-31	PR
Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti? for the Treatments of Acute Bipolar I Disorder and Schizophrenia	03-31	CI
Vanda Raises Concerns Over FDA Review Timeline for Motion Sickness Therapy Candidate	03-17	MT
Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"	02-24	PR
Vanda Pharmaceuticals Inc. Announces the Publication of an Article Article Entitled "Potential ASO-Based Personalized Treatment for Charcot-Marie-Tooth Disease Type 2S	02-24	CI
Vanda Pharmaceuticals Inc., Q4 2024 Earnings Call, Feb 13, 2025	02-13
Vanda: Q4 Earnings Snapshot	02-13	AQ
Vanda Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024	02-13	CI
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results	02-13	PR
Vanda Pharmaceuticals Inc. Provides Revenue Guidance for the Year 2025 and 2030	02-13	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Biotechnology & Medical Research

Filters